Remdesivir improves symptoms in Covid-19 patients treated early, study finds
Gilead says its study shows that 62% of patients treated early were discharged from hospital, compared to 49% of patients who were treated late
29 April 2020 - 15:30
Bengaluru — Gilead Sciences' experimental antiviral drug remdesivir helped improve symptoms in Covid-19 patients who were given the drug early, rather than among those who were treated later, the company said.
The closely watched drug has moved markets in the past few weeks and on Wednesday broader markets once again rose on the data and Gilead shares also jumped 9%...
Would you like to comment on this article?
Sign up (it's quick and free) or sign in now.
Please read our Comment Policy before commenting.
Subscribe now to unlock this article.
Support BusinessLIVE’s award-winning journalism for R129 per month (digital access only).
There’s never been a more important time to support independent journalism in SA. Our subscription packages now offer an ad-free experience for readers.
Cancel anytime.
Questions? Email helpdesk@businesslive.co.za or call 0860 52 52 00. Got a subscription voucher? Redeem it now.